Search Result

Pathways Recommended:	MAPK/ERK Pathway

Results for "

glycolytic pathways

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ACSL Family (1) Cuproptosis (1) DNA/RNA Synthesis (2) Endogenous Metabolite (11) Ferroptosis (1) Flavivirus (2) Glutathione Peroxidase (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) Lactate Dehydrogenase (3) Mitochondrial Metabolism (1) Monocarboxylate Transporter (1) Parasite (4) PD-1/PD-L1 (1) PDHK (1) Phosphatase (2) Phosphoglycerate Kinase (PGK) (1) Pyruvate Kinase (4) Reactive Oxygen Species (ROS) (7) Reference Standards (1) SARS-CoV (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (5) Metabolic Disease (14) Neurological Disease (4)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W015913

Pyruvic acid sodium 15+ Cited Publications Sodium 2-oxopropanoate; Acetylformic acid sodium	Reactive Oxygen Species (ROS) Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-12689

Mitapivat 3 Publications Verification AG-348	Pyruvate Kinase	Metabolic Disease
Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .

HY-W015913S

Pyruvic acid-13C3 sodium 1 Publications Verification Sodium 2-oxopropanoate-13C3; Acetylformic acid-13C3 sodium	Reactive Oxygen Species (ROS) Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate- ¹³C₃ is the ¹³C-labeled Sodium 2-oxopropanoate. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-113167

2-Phosphoglyceric acid DL-2-phosphoglyceric acid	ACSL Family Endogenous Metabolite Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS)	Metabolic Disease
2-Phosphoglyceric acid (DL-2-phosphoglyceric acid) is a glycolytic substrate that is catalyzed by enolase to form phosphoenolpyruvate ester (PEP). 2-Phosphoglyceric acid inhibits the ferroptosis pathway by down-regulating ACSL4 and up-regulating GPX4, and has significant neuroprotective effects. 2-Phosphoglyceric acid reflects the overall metabolic state and flux of the cell .

HY-W587427

D-2-Phosphoglyceric acid trisodium	Endogenous Metabolite Monocarboxylate Transporter	Neurological Disease Cancer
D-2-Phosphoglyceric acid trisodium is a glycolysis and gluconeogenesis intermediate with altered levels linked to MCT4-modulated glycolytic pathways. D-2-Phosphoglyceric acid trisodium shows reduced intracellular levels in hypoxic glioblastoma stem cells after MCT4 knockdown. D-2-Phosphoglyceric acid trisodium can be used for the research of glioblastoma .

HY-W015913S3

Pyruvic acid-13C-1 sodium Sodium 2-oxopropanoate-13C; Acetylformic acid-13C-1 sodium	Endogenous Metabolite Reactive Oxygen Species (ROS)	Metabolic Disease
Sodium 2-oxopropanoate- ¹³C is the ¹³C labeled Sodium 2-oxopropanoate . Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-113050

2,3-Diphosphoglyceric acid 2,3-DPG	Parasite	Infection Neurological Disease
2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

HY-128788

ddhCTP	DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase	Infection
ddhCTP is an endogenously produced pyrimidine base analog with a K_d of 17.0 nM for LLDH and an IC₅₀ of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP can be used in studies related to viral infections, COVID-19 and Zika virus infections.

HY-113050A

2,3-Diphosphoglyceric acid pentasodium 2,3-DPG pentasodium	Parasite	Others
2,3-Diphosphoglyceric acid (2,3-DPG) pentasodium is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid pentasodium stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2,3-Diphosphoglyceric acid pentasodium binds to hemoglobin and decrease its affinity for oxygen .

HY-P2819

Phosphofructokinase 1 PFK1	Phosphatase	Metabolic Disease
Phosphofructokinase 1 (PFK1) is a major regulatory enzyme targeting glycolytic pathway. Phosphofructokinase 1 catalyzes the phosphorylation of fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (F1,6BP) to regulate glycolytic flux. Phosphofructokinase 1 is promising for research of cancer metabolic reprogramming (e.g., hypoxia adaptation, oxidative stress resistance) and metabolic syndromes .

HY-178989

PGK1-IN-2	Phosphoglycerate Kinase (PGK) Cuproptosis	Cancer
PGK1-IN-2 (Compound 60) is a PGK1 inhibitor with an IC₅₀ of 8.24 μM. PGK1-IN-2 demonstrates a significant ability to inhibit the proliferation of osteosarcoma cells. PGK1-IN-2 interferes with the glycolytic pathway of tumor cells by inhibiting PGK1. PGK1-IN-2 inhibits cell migration and invasion, and induces cell S phase and G2-M phase cycle arrest. PGK1-IN-2 may kill cells by inducing cuproptosis. PGK1-IN-2 shows a significant anti-tumor effect in the MNNG-HOS osteosarcoma xenograft mouse model. PGK1-IN-2 can be used for the study of osteosarcoma .

HY-W015913R

Pyruvic acid sodium (Standard) 5+ Cited Publications Sodium 2-oxopropanoate (Standard); Acetylformic acid sodium (Standard)	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite	Metabolic Disease
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-169436

Lon-TK	PD-1/PD-L1
Lon-TK is a glycolysis inhibitor + linker conjugate of LTB (HY-169434). LTB is an intelligent responsive prodrug that connects Lonidamine (Lon) (HY-B0486) and a PD-L1 inhibitor (BMS-1, HY-19991) through a thioketal linker. It significantly inhibits the glycolytic metabolism of tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK shows potential for application in photodynamic-enhanced immunotherapy research .

HY-159495

Keap1-Nrf2-IN-21	Keap1-Nrf2	Metabolic Disease Cancer
Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC₅₀=2.60 μM) .

HY-138877A

Phosphoglycolic acid lithium	Phosphatase	Cancer
Phosphoglycolic acid (lithium) is a competitive inhibitor of phosphoglycerate mutase (PGAM)-B, an enzyme of the glycolytic pathway. Phosphoglycolic acid increases basal and fMLF-induced levels of G6P in intact neutrophils. Phosphoglycolic acid thereby increases upstream intermediates in neutrophils, thereby amplifying the respiratory oxidative burst .

HY-W015913S1

Pyruvic acid-d3 sodium Sodium 2-oxopropanoate-d3; Acetylformic acid-d3 sodium	Endogenous Metabolite Reactive Oxygen Species (ROS)	Metabolic Disease
Sodium 2-oxopropanoate-d₃ is the deuterium labeled Sodium 2-oxopropanoate . Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-W015913S4

Pyruvic acid-13C2-1 sodium Sodium 2-oxopropanoate-13C2; Acetylformic acid-13C2-1 sodium	Endogenous Metabolite Reactive Oxygen Species (ROS)	Metabolic Disease
2-Oxopropanoate- ¹³C₂ (sodium) is the ¹³C labeled Sodium 2-oxopropanoate . Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-12689B

Mitapivat hemisulfate AG-348 hemisulfate	Pyruvate Kinase	Metabolic Disease
Mitapivat hemisulfate is an orally active pyruvate kinase allosteric activator. Mitapivat hemisulfate increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat hemisulfate can be used in study of PK deficiency .

HY-12689A

Mitapivat hemisulfate sesquihydrate AG-348 hemisulfate sesquihydrate	Pyruvate Kinase	Metabolic Disease
Mitapivat hemisulfate sesquihydrate (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .

HY-156109

PDK-IN-2	PDHK Mitochondrial Metabolism	Cancer
PDK-IN-2 (Compound 1F) is a PDK inhibitor (IC₅₀: 68 nM). PDK-IN-2 inhibits the cellular expression of PDK1 and PDK4. PDK-IN-2 enhances mitochondrial bioenergetics, attenuates glycolytic phenotypes, and induces cell apoptosis in the mitochondrial pathway. PDK-IN-2 inhibits tumor growth in 4T1 syngeneic mice model .

HY-12689C

Mitapivat hydrochloride AG-348 hydrochloride	Pyruvate Kinase	Cardiovascular Disease Metabolic Disease
Mitapivat (AG-348) hydrochloride is an orally active and selective allosteric pyruvate kinase R (PK-R) activator. Mitapivat hydrochloride accelerates the reaction of PK-R catalyzing the conversion of phosphoenolpyruvate to pyruvate, thereby promoting the glycolytic pathway, increasing the production of adenosine triphosphate (ATP) in red blood cells, and reducing the level of 2,3-diphosphoglycerate (2,3-DPG). Mitapivat hydrochloride is promising for research of pyruvate kinase deficiency and other anemia-related diseases .

HY-113050SA

2,3-Diphosphoglyceric acid-d3 ammonium 2,3-DPG-d3 ammonium	Isotope-Labeled Compounds Parasite	Infection Neurological Disease
2,3-Diphosphoglyceric acid-d3 ammonium (2,3-DPG-d3 ammonium) is the deuterium labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

HY-W751808S

2,3-Diphosphoglyceric acid-13C3 2,3-DPG-¹³C₃	Isotope-Labeled Compounds Parasite	Infection Neurological Disease
2,3-Diphosphoglyceric acid- ¹³C₃ is the ¹³C-labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

HY-128788A

ddhCTP trisodium solution (100 mM)	DNA/RNA Synthesis SARS-CoV Endogenous Metabolite Flavivirus Lactate Dehydrogenase	Infection
ddhCTP trisodium solution (100 mM) is an endogenously produced pyrimidine base analog with a K_d of 17.0 nM for LLDH and an IC₅₀ of 55.8 μM for GAPDH. By inhibiting key metabolic enzymes such as GAPDH, ddhCTP trisodium reduces glycolytic flux and shifts metabolic flow toward the pentose phosphate pathway, thereby regulating the redox balance of cells. As a competitive CTP analog, ddhCTP trisodium terminates RNA synthesis by flavivirus RdRps and SARS-CoV-2 RdRp, and inhibits Zika virus replication in vivo. ddhCTP trisodium can be used in studies related to viral infections, COVID-19 and Zika virus infections .

HY-E70976

3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae)	Endogenous Metabolite	Metabolic Disease
3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae) (EC 2.7.2.3) is an enzyme that catalyzes the reversible transfer of a phosphate group from 1,3-bisphosphoglyceRate (1,3-BPG) to ADP producing 3-phosphoglyceRate (3-PG) and ATP. 3-Phosphoglyceric Phosphokinase, Baker's yeast (S. cerevisiae) (EC 2.7.2.3) is a transferase. 3-Phosphoglyceric Phosphokinase is a major enzyme used in glycolysis, in the first ATP-geneRating step of the glycolytic pathway. In gluconeogenesis, the reaction catalyzed by 3-Phosphoglyceric Phosphokinase proceeds in the opposite direction, geneRating ADP and 1,3-BPG.

HY-183858

NCATS-SM1440	Lactate Dehydrogenase	Cancer
NCATS-SM1440 is a glycolysis inhibitor and metabolic regulator that targets LDHA and LDHB (IC₅₀=0.06 μM and 0.03 μM, respectively). Upon binding to LDHA, NCATS-SM1440 blocks the glycolysis pathway and reduces lactate production. NCATS-SM1440 drives the shift of pyruvate metabolism toward mitochondrial metabolism, effectively disrupting the dependence of cancer cells on aerobic glycolysis. NCATS-SM1440 can be widely used in research related to cancer, Ewing's sarcoma, and other related conditions .

Cat. No.	Product Name

HY-L083

Anti-Cancer Metabolism Compound Library	3,552 compounds
Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth. MCE provides a unique collection of 3,552 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

Anti-Cancer Metabolism Compound Library

3,552 compounds

Mutations in oncogenes and tumor suppressor genes can modify multiple signaling pathways and in turn cell metabolism, which facilitates tumorigenesis. The paramount hallmark of tumor metabolism is “aerobic glycolysis” or the Warburg effect, coined by Otto Warburg in 1926, in which cancer cells produce most of energy from glycolysis pathway regardless of whether in aerobic or anaerobic condition. Usually, cancer cells are highly glycolytic (glucose addiction) and take up more glucose than do normal cells from outside. The increased uptake of glucose is facilitated by the overexpression of several isoforms of membrane glucose transporters (GLUTs). Likewise, the metabolic pathways of glutamine, amino acid and fat metabolism are also altered. Recent trends in anti-cancer drug discovery suggests that targeting the altered metabolic pathways of cancer cells result in energy crisis inside the cancer cells and can selectively inhibit cancer cell proliferation by delaying or suppressing tumor growth.

MCE provides a unique collection of 3,552 compounds which cover various tumor metabolism-related signaling pathways. These compounds can be used for anti-cancer metabolism targets identification, validation as well anti-cancer drug discovery.

HY-L249

Lactylation Compound Library	5,860 compounds
Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis. MCE has assembled a collection of 5,860 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

Lactylation Compound Library

5,860 compounds

Protein lactylation, an emerging post-translational modification identified in recent years, plays a critical role in linking cellular metabolic reprogramming, epigenetic regulation, and signaling networks. Based on a systematic framework encompassing lactate metabolism, lactylation, and downstream signaling pathways, this compound library comprehensively targets multiple regulatory layers, including histone modification enzymes (such as p300 and HDACs), key glycolytic enzymes (such as PKM2, LDHA, and GAPDH), transcriptional regulators (such as STAT3, HMGB1, and p53), as well as central signaling pathway nodes including HIF-1α, NF-κB, and PI3K-AKT-mTOR. This integrated design enables a comprehensive representation of the regulatory roles of lactylation across the “metabolism–epigenetics–signaling” axis.

MCE has assembled a collection of 5,860 known bioactive compounds and potential functional molecules, making this library suitable for a wide range of applications, including high-throughput drug screening, inhibitor identification, and mechanistic studies. It can be used to systematically evaluate the functional roles of lactylation in biological processes such as tumor metabolism, immune regulation, and inflammatory responses, and to efficiently identify small-molecule candidates with regulatory potential, thereby facilitating the development of innovative therapeutics targeting the interplay between metabolism and epigenetic regulation.

HY-L058

Glycolysis Compound Library	1,258 compounds
Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation. Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications. MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Glycolysis Compound Library

1,258 compounds

Glycolysis is a series of metabolic processes by which one molecule of glucose is catabolized to two molecules of pyruvate with a net gain of two ATP. Glycolysis takes place in 10 steps and catalyzed by a series of enzyme, such as hexokinase, Glucose-6-phosphate isomerase, Phosphofructokinase, etc. Glycolysis is used by all cells in the body for energy generation.

Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.

MCE provides a unique collection of 1,258 glycolysis compounds that mainly target hexokinase, glucokinase, enolase, pyruvate kinase, PDHK, etc. MCE Glycolysis Compound Library is a useful tool for glucose metabolism research and anti-cancer drug discovery.

Cat. No.	Product Name	Type

HY-W015913

Pyruvic acid sodium 15+ Cited Publications Sodium 2-oxopropanoate; Acetylformic acid sodium	Biochemical Assay Reagents
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-W015913R

Pyruvic acid sodium (Standard) 5+ Cited Publications Sodium 2-oxopropanoate (Standard); Acetylformic acid sodium (Standard)	Biochemical Assay Reagents
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015913

Pyruvic acid sodium 15+ Cited Publications Sodium 2-oxopropanoate; Acetylformic acid sodium	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	Reactive Oxygen Species (ROS) Endogenous Metabolite
Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-113167

2-Phosphoglyceric acid DL-2-phosphoglyceric acid	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification	ACSL Family Endogenous Metabolite Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS)
2-Phosphoglyceric acid (DL-2-phosphoglyceric acid) is a glycolytic substrate that is catalyzed by enolase to form phosphoenolpyruvate ester (PEP). 2-Phosphoglyceric acid inhibits the ferroptosis pathway by down-regulating ACSL4 and up-regulating GPX4, and has significant neuroprotective effects. 2-Phosphoglyceric acid reflects the overall metabolic state and flux of the cell .

HY-W015913R

Pyruvic acid sodium (Standard) 5+ Cited Publications Sodium 2-oxopropanoate (Standard); Acetylformic acid sodium (Standard)	Structural Classification Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Reactive Oxygen Species (ROS) Endogenous Metabolite
Sodium 2-oxopropanoate (Standard) is the analytical standard of Sodium 2-oxopropanoate. This product is intended for research and analytical applications. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

Cat. No.	Product Name	Chemical Structure

HY-W015913S

Pyruvic acid-13C3 sodium 1 Publications Verification
Sodium 2-oxopropanoate- ¹³C₃ is the ¹³C-labeled Sodium 2-oxopropanoate. Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-W015913S3

Pyruvic acid-13C-1 sodium
Sodium 2-oxopropanoate- ¹³C is the ¹³C labeled Sodium 2-oxopropanoate . Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-W015913S1

Pyruvic acid-d3 sodium
Sodium 2-oxopropanoate-d₃ is the deuterium labeled Sodium 2-oxopropanoate . Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-W015913S4

Pyruvic acid-13C2-1 sodium
2-Oxopropanoate- ¹³C₂ (sodium) is the ¹³C labeled Sodium 2-oxopropanoate . Sodium 2-oxopropanoate (Sodium pyruvate), a three-carbon metabolite of Glucose, is a compound produced in the glycolytic pathway. Sodium 2-oxopropanoate is a free radical scavenger that can scavenge ROS .

HY-113050SA

2,3-Diphosphoglyceric acid-d3 ammonium
2,3-Diphosphoglyceric acid-d3 ammonium (2,3-DPG-d3 ammonium) is the deuterium labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

2,3-Diphosphoglyceric acid-d3 ammonium

2,3-Diphosphoglyceric acid-d3 ammonium (2,3-DPG-d3 ammonium) is the deuterium labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

HY-W751808S

2,3-Diphosphoglyceric acid-13C3
2,3-Diphosphoglyceric acid- ¹³C₃ is the ¹³C-labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

2,3-Diphosphoglyceric acid-13C3

2,3-Diphosphoglyceric acid- ¹³C₃ is the ¹³C-labeled 2,3-Diphosphoglyceric acid (HY-113050). 2,3-Diphosphoglyceric acid (2,3-DPG) is an intermediate of the glycolytic pathway. 2,3-Diphosphoglyceric acid stabilizes the deoxygenated form of hemoglobin by allosteric binding and facilitates oxygen release at tissue sites. 2, 3-diphosphoglyceric acid has antiparasitic activity. 2,3-Diphosphoglyceric acid can be used in the study of Alzheimer's disease (AD) .

Cat. No.	Product Name		Classification

HY-159495

Keap1-Nrf2-IN-21		Azide
Keap1-Nrf2-IN-21 (compound 4d) is a glucose metabolism inhibitor with antitumor activity. Keap1-Nrf2-IN-21 inhibits glycolytic activity of cancer cells by targeting the glycolytic pathway, especially by affecting the Keap1-Nrf2 signaling pathway, thereby inhibiting tumor growth. Keap1-Nrf2-IN-21 exhibits cytotoxicity against the HEC1A cell line (IC₅₀=2.60 μM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

glycolytic pathways

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products